.png)
Human Vaccines Market by Product Type and End User - Global Industry Analysis & Forecast to 2027
Published On : May 2022 Pages : 166 Category: Pharma & Healthcare Report Code : HC053546
SEGMENTS & REGIONS:
- Regions: North America, Europe, Asia- Pacific, Latin America, Middle East & Africa
Human Vaccines Market by Product Type (Measles-RubellaVaccine, Dengue Vaccine, TD Vaccine, Chikungunya Vaccine, Hepatitis A Vaccine, Zika Vaccine, Typhoid Conjugate Vaccine) End User (Children, Adults) - Global Industry Analysis & Forecast to 2027
Industry Outlook and Trend Analysis
The Human Vaccines Market has encountered significant development over the recent years and is anticipated to grow tremendously over the forecast period. Vaccination is always promoted as essential general wellbeing mediation over the globe for quite a long time. As per the World Health Organization (WHO), vaccinations have helped diminish the worldwide weight of irresistible malady all things considered. The low risk of severe and lethal symptoms related with immunizations and developing awareness in regards to inoculation by different government and non-benefit associations are the key variables driving the human vaccines market.
Drivers and Restraints
The worldwide human vaccines market could have an inspirational viewpoint as far as development for the following couple of years. Nonetheless, increasing expense of human vaccines and their storage, transportation, and dealing with is conceived to hose the interest in the market. Moreover, tight administrative demands could make it hard for producers to approach their activity easily. In any case, the eventual fate of the market still looks splendid with telling increment in inoculation rate saw in independent drug stores working in developed nations.
Regional Insights
North America was the prevailing business sector for human vaccines regarding income in 2017 inferable from the developing interest for inoculation among grown-ups and youngsters. The market is likewise powered by the expansion in government endeavors toward immunization programs and the way that most antibodies are accessible in the U.S.
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Southeast Asia
- Rest of Asia-Pacific
- South America
- Brazil
- Argentina
- Columbia
- Rest of South America
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Nigeria
- South Africa
- Rest of MEA
Competitive Analysis
The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and share of the overall industry.
- Merck & Co., Inc.
- AstraZeneca
- Johnson & Johnson
- GlaxoSmithKline plc
- Sanofi
- Pfizer, Inc
- Novartis AG
- Bharat Biotech
- Emergent BioSolutions, Inc.
- CSL Limited
- Bavarian Nordic
- Shenzhen Kangtai Biological Products Co., Ltd
Some of the key questions answered by the report are:
- What was the market size in 2017 and forecast from 2017 to 2027?
- What will be the industry market growth from 2017 to 2027?
- What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
- What are the major segments leading the market growth and why?
- Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?
Market Classification
· Human Vaccines Market, By Product Type, Estimates and Forecast, 2017-2027 ($Million)
o Measles-RubellaVaccine
o Dengue Vaccine
o TD Vaccine
o Chikungunya Vaccine
o Hepatitis A Vaccine
o Zika Vaccine
o Typhoid Conjugate Vaccine
· Human Vaccines Market, By End User, Estimates and Forecast, 2017-2027 ($Million)
o Children
o Adults
· Human Vaccines Market, By Key Players
o Merck & Co., Inc.
o AstraZeneca
o Johnson & Johnson
o GlaxoSmithKline plc
o Sanofi
o Pfizer, Inc
o Novartis AG
o Bharat Biotech
o Emergent BioSolutions, Inc.
o CSL Limited
o Bavarian Nordic
o Shenzhen Kangtai Biological Products Co., Ltd
· Human Vaccines Market, By Region, Estimates and Forecast, 2017-2027 ($Million)
o North America
§ North America Human Vaccines Market, By Country
o U.S. Human Vaccines Market
o Canada Human Vaccines Market
o Mexico Human Vaccines Market
o Europe
§ Europe Human Vaccines Market, By Country
o Germany Human Vaccines Market
o UK Human Vaccines Market
o France Human Vaccines Market
o Russia Human Vaccines Market
o Italy Human Vaccines Market
o Rest of Europe Human Vaccines Market
o Asia-Pacific
§ Asia-Pacific Human Vaccines Market, By Country
o China Human Vaccines Market
o Japan Human Vaccines Market
o South Korea Human Vaccines Market
o India Human Vaccines Market
o Southeast Asia Human Vaccines Market
o Rest of Asia-Pacific Human Vaccines Market
o South America
§ South America Human Vaccines Market
o Brazil Human Vaccines Market
o Argentina Human Vaccines Market
o Columbia Human Vaccines Market
o Rest of South America Human Vaccines Market
o Middle East and Africa
§ Middle East and Africa Human Vaccines Market
o Saudi Arabia Human Vaccines Market
o UAE Human Vaccines Market
o Egypt Human Vaccines Market
o Nigeria Human Vaccines Market
o South Africa Human Vaccines Market
o Rest of MEA Human Vaccines Market
Table of Contents:
1. Introduction
1.1. Report Description
2. Executive Summary
2.1. Key Highlights
3. Market Overview
3.1. Introduction
3.1.1. Market Definition
3.1.2. Market Segmentation
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
4. Market Analysis by Regions
4.1. North America (United States, Canada and Mexico)
4.1.1. United States Market Status and Outlook (2017-2027)
4.1.2. Canada Market Status and Outlook (2017-2027)
4.1.3. Mexico Market Status and Outlook (2017-2027)
4.2. Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
4.2.1. Germany Market Status and Outlook (2017-2027)
4.2.2. France Market Status and Outlook (2017-2027)
4.2.3. UK Market Status and Outlook (2017-2027)
4.2.4. Russia Market Status and Outlook (2017-2027)
4.2.5. Italy Market Status and Outlook (2017-2027)
4.2.6. Rest of Europe Market Status and Outlook (2017-2027)
4.3. Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Rest of Asia-Pacific)
4.3.1. China Market Status and Outlook (2017-2027)
4.3.2. Japan Market Status and Outlook (2017-2027)
4.3.3. Korea Market Status and Outlook (2017-2027)
4.3.4. India Market Status and Outlook (2017-2027)
4.3.5. Southeast Asia Market Status and Outlook (2017-2027)
4.3.6. Rest of Asia-Pacific Market Status and Outlook (2017-2027)
4.4. South America (Brazil, Argentina, Columbia and Rest of South America)
4.4.1. Brazil Market Status and Outlook (2017-2027)
4.4.2. Argentina Market Status and Outlook (2017-2027)
4.4.3. Columbia Market Status and Outlook (2017-2027)
4.4.4. Rest of South America Market Status and Outlook (2017-2027)
4.5. Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of MEA)
4.5.1. Saudi Arabia Market Status and Outlook (2017-2027)
4.5.2. United Arab Emirates Market Status and Outlook (2017-2027)
4.5.3. Egypt Market Status and Outlook (2017-2027)
4.5.4. Nigeria Market Status and Outlook (2017-2027)
4.5.5. South Africa Market Status and Outlook (2017-2027)
4.5.6. Turkey Market Status and Outlook (2017-2027)
4.5.7. Rest of Middle East and Africa Market Status and Outlook (2017-2027)
5. Human Vaccines Market, By Product Type
5.1. Introduction
5.2. Global Human Vaccines Revenue and Market Share by Product Type (2017-2027)
5.2.1. Global Human Vaccines Revenue and Revenue Share by Product Type (2017-2027)
5.3. Measles-RubellaVaccine
5.3.1. Global Measles-RubellaVaccine Revenue and Growth Rate (2017-2027)
5.4. Dengue Vaccine
5.4.1. Global Dengue Vaccine Revenue and Growth Rate (2017-2027)
5.5. TD Vaccine
5.5.1. Global TD Vaccine Revenue and Growth Rate (2017-2027)
5.6. Chikungunya Vaccine
5.6.1. Global Chikungunya Vaccine Revenue and Growth Rate (2017-2027)
5.7. Hepatitis A Vaccine
5.7.1. Global Hepatitis A Vaccine Revenue and Growth Rate (2017-2027)
5.8. Zika Vaccine
5.8.1. Global Zika Vaccine Revenue and Growth Rate (2017-2027)
5.9. Typhoid Conjugate Vaccine
5.9.1. Global Typhoid Conjugate Vaccine Revenue and Growth Rate (2017-2027)
6. Human Vaccines Market, By End User
6.1. Introduction
6.2. Global Human Vaccines Revenue and Market Share by End User (2017-2027)
6.2.1. Global Human Vaccines Revenue and Revenue Share by End User (2017-2027)
6.3. Children
6.3.1. Global Children Revenue and Growth Rate (2017-2027)
6.4. Adults
6.4.1. Global Adults Revenue and Growth Rate (2017-2027)
7. Human Vaccines Market, By Region
7.1. Introduction
7.2. Global Human Vaccines Revenue and Market Share by Regions
7.2.1. Global Human Vaccines Revenue by Regions (2017-2027)
7.3. North America Human Vaccines by Countries
7.3.1. North America Human Vaccines Revenue and Growth Rate (2017-2027)
7.3.2. North America Human Vaccines Revenue (Million USD) by Countries (2017-2027)
7.3.3. United States
7.3.3.1. United States Human Vaccines Revenue (Millions USD) and Growth Rate (2017-2027)
7.3.4. Canada
7.3.4.1. Canada Human Vaccines Revenue (Millions USD) and Growth Rate (2017-2027)
7.3.5. Mexico
7.3.5.1. Mexico Human Vaccines Revenue (Millions USD) and Growth Rate (2017-2027)
7.4. Europe Human Vaccines by Countries
7.4.1. Europe Human Vaccines Revenue and Growth Rate (2017-2027)
7.4.2. Europe Human Vaccines Revenue (Million USD) by Countries (2017-2027)
7.4.3. Germany
7.4.3.1. Germany Human Vaccines Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.4. France
7.4.4.1. France Human Vaccines Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.5. UK
7.4.5.1. UK Human Vaccines Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.6. Russia
7.4.6.1. Russia Human Vaccines Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.7. Italy
7.4.7.1. Italy Human Vaccines Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.8. Rest of Europe
7.4.8.1. Rest of Europe Human Vaccines Revenue (Millions USD) and Growth Rate (2017-2027)
7.5. Asia-Pacific Human Vaccines by Countries
7.5.1. Asia-Pacific Human Vaccines Revenue and Growth Rate (2017-2027)
7.5.2. Asia-Pacific Human Vaccines Revenue (Million USD) by Countries (2017-2027)
7.5.3. China
7.5.3.1. China Human Vaccines Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.4. Japan
7.5.4.1. Japan Human Vaccines Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.5. Korea
7.5.5.1. Korea Human Vaccines Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.6. India
7.5.6.1. India Human Vaccines Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.7. Southeast Asia
7.5.7.1. Southeast Asia Human Vaccines Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.8. Rest of Asia-Pacific
7.5.8.1. Rest of Asia-Pacific Human Vaccines Revenue (Millions USD) and Growth Rate (2017-2027)
7.6. South America Human Vaccines by Countries
7.6.1. South America Human Vaccines Revenue and Growth Rate (2017-2027)
7.6.2. South America Human Vaccines Revenue (Million USD) by Countries (2017-2027)
7.6.3. Brazil
7.6.3.1. Brazil Human Vaccines Revenue (Millions USD) and Growth Rate (2017-2027)
7.6.4. Argentina
7.6.4.1. Argentina Human Vaccines Revenue (Millions USD) and Growth Rate (2017-2027)
7.6.5. Columbia
7.6.5.1. Columbia Human Vaccines Revenue (Millions USD) and Growth Rate (2017-2027)
7.6.6. Rest of South America
7.6.6.1. Rest of South America Human Vaccines Revenue (Millions USD) and Growth Rate (2017-2027)
7.7. Middle East and Africa Human Vaccines by Countries
7.7.1. Middle East and Africa Human Vaccines Revenue and Growth Rate (2017-2027)
7.7.2. Middle East and Africa Human Vaccines Revenue (Million USD) by Countries (2017-2027)
7.7.3. Saudi Arabia
7.7.3.1. Saudi Arabia Human Vaccines Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.4. United Arab Emirates
7.7.4.1. United Arab Emirates Human Vaccines Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.5. Egypt
7.7.5.1. Egypt Human Vaccines Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.6. Nigeria
7.7.6.1. Nigeria Human Vaccines Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.7. South Africa
7.7.7.1. South Africa Human Vaccines Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.8. Turkey
7.7.8.1. Turkey Human Vaccines Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.9. Rest of Middle East and Africa
7.7.9.1. Rest of Middle East and Africa Human Vaccines Revenue (Millions USD) and Growth Rate (2017-2027)
8. Company Profiles
8.1. Merck & Co., Inc.
8.1.1. Business Overview
8.1.2. Service Portfolio
8.1.3. Strategic Developments
8.1.4. Financial Overview
8.2. AstraZeneca
8.2.1. Business Overview
8.2.2. Service Portfolio
8.2.3. Strategic Developments
8.2.4. Financial Overview
8.3. Johnson & Johnson
8.3.1. Business Overview
8.3.2. Service Portfolio
8.3.3. Strategic Developments
8.3.4. Financial Overview
8.4. GlaxoSmithKline plc
8.4.1. Business Overview
8.4.2. Service Portfolio
8.4.3. Strategic Developments
8.4.4. Financial Overview
8.5. Sanofi
8.5.1. Business Overview
8.5.2. Service Portfolio
8.5.3. Strategic Developments
8.5.4. Financial Overview
8.6. Pfizer, Inc.
8.6.1. Business Overview
8.6.2. Service Portfolio
8.6.3. Strategic Developments
8.6.4. Financial Overview
8.7. Novartis AG
8.7.1. Business Overview
8.7.2. Service Portfolio
8.7.3. Strategic Developments
8.7.4. Financial Overview
8.8. Bharat Biotech
8.8.1. Business Overview
8.8.2. Service Portfolio
8.8.3. Strategic Developments
8.8.4. Financial Overview
8.9. Emergent BioSolutions, Inc.
8.9.1. Business Overview
8.9.2. Service Portfolio
8.9.3. Strategic Developments
8.9.4. Financial Overview
8.10. CSL Limited
8.10.1. Business Overview
8.10.2. Service Portfolio
8.10.3. Strategic Developments
8.10.4. Financial Overview
8.11. Bavarian Nordic
8.11.1. Business Overview
8.11.2. Service Portfolio
8.11.3. Strategic Developments
8.11.4. Financial Overview
8.12. Shenzhen Kangtai Biological Products Co., Ltd.
8.12.1. Business Overview
8.12.2. Service Portfolio
8.12.3. Strategic Developments
8.12.4. Financial Overview
9. Human Vaccines Market Forecast (2017-2027)
9.1. Global Human Vaccines Revenue (Millions USD) and Growth Rate (2017-2027)
9.2. Human Vaccines Market Forecast by Regions (2017-2027)
9.2.1. North America Human Vaccines Market Forecast (2017-2027)
9.2.1.1. United States Human Vaccines Market Forecast (2017-2027)
9.2.1.2. Canada Human Vaccines Market Forecast (2017-2027)
9.2.1.3. Mexico Human Vaccines Market Forecast (2017-2027)
9.2.2. Europe Human Vaccines Market Forecast (2017-2027)
9.2.2.1. Germany Human Vaccines Market Forecast (2017-2027)
9.2.2.2. France Human Vaccines Market Forecast (2017-2027)
9.2.2.3. UK Human Vaccines Market Forecast (2017-2027)
9.2.2.4. Russia Human Vaccines Market Forecast (2017-2027)
9.2.2.5. Italy Human Vaccines Market Forecast (2017-2027)
9.2.2.6. Rest of Europe Human Vaccines Market Forecast (2017-2027)
9.2.3. Asia-Pacific Human Vaccines Market Forecast (2017-2027)
9.2.3.1. China Human Vaccines Market Forecast (2017-2027)
9.2.3.2. Japan Human Vaccines Market Forecast (2017-2027)
9.2.3.3. Korea Human Vaccines Market Forecast (2017-2027)
9.2.3.4. India Human Vaccines Market Forecast (2017-2027)
9.2.3.5. Southeast Asia Human Vaccines Market Forecast (2017-2027)
9.2.3.6. Rest of Asia-Pacific Human Vaccines Market Forecast (2017-2027)
9.2.4. South America Human Vaccines Market Forecast (2017-2027)
9.2.4.1. Brazil Human Vaccines Market Forecast (2017-2027)
9.2.4.2. Argentina Human Vaccines Market Forecast (2017-2027)
9.2.4.3. Columbia Human Vaccines Market Forecast (2017-2027)
9.2.4.4. Rest of South America Human Vaccines Market Forecast (2017-2027)
9.2.5. Middle East and Africa Human Vaccines Market Forecast (2017-2027)
9.2.5.1. Saudi Arabia Human Vaccines Market Forecast (2017-2027)
9.2.5.2. United Arab Emirates Human Vaccines Market Forecast (2017-2027)
9.2.5.3. Egypt Human Vaccines Market Forecast (2017-2027)
9.2.5.4. Nigeria Human Vaccines Market Forecast (2017-2027)
9.2.5.5. South Africa Human Vaccines Market Forecast (2017-2027)
9.2.5.6. Turkey Human Vaccines Market Forecast (2017-2027)
9.2.5.7. Rest of Middle East and Africa Human Vaccines Market Forecast (2017-2027)
9.3. Human Vaccines Market Forecast by Product Type (2017-2027)
9.3.1. Human Vaccines Forecast by Product Type (2017-2027)
9.3.2. Human Vaccines Market Share Forecast by Product Type (2017-2027)
9.4. Human Vaccines Market Forecast by End User (2017-2027)
9.4.1. Human Vaccines Forecast by End User (2017-2027)
9.4.2. Human Vaccines Market Share Forecast by End User (2017-2027)
List of Tables
List of Tables and Figures:
Figure United States Human Vaccines Revenue (Million USD) and Growth Rate (2017-2025)
Figure Canada Human Vaccines Revenue (Million USD) and Growth Rate (2017-2025)
Figure Mexico Human Vaccines Revenue (Million USD) and Growth Rate (2017-2025)
Figure Germany Human Vaccines Revenue (Million USD) and Growth Rate (2017-2025)
Figure France Human Vaccines Revenue (Million USD) and Growth Rate (2017-2025)
Figure UK Human Vaccines Revenue (Million USD) and Growth Rate (2017-2025)
Figure Russia Human Vaccines Revenue (Million USD) and Growth Rate (2017-2025)
Figure Italy Human Vaccines Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Europe Human Vaccines Revenue (Million USD) and Growth Rate (2017-2025)
Figure China Human Vaccines Revenue (Million USD) and Growth Rate (2017-2025)
Figure Japan Human Vaccines Revenue (Million USD) and Growth Rate (2017-2025)
Figure Korea Human Vaccines Revenue (Million USD) and Growth Rate (2017-2025)
Figure India Human Vaccines Revenue (Million USD) and Growth Rate (2017-2025)
Figure Southeast Asia Human Vaccines Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Asia-Pacific Human Vaccines Revenue (Million USD) and Growth Rate (2017-2025)
Figure Brazil Human Vaccines Revenue (Million USD) and Growth Rate (2017-2025)
Figure Argentina Human Vaccines Revenue (Million USD) and Growth Rate (2017-2025)
Figure Columbia Human Vaccines Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of South America Human Vaccines Revenue (Million USD) and Growth Rate (2017-2025)
Figure Saudi Arabia Human Vaccines Revenue (Million USD) and Growth Rate (2017-2025)
Figure United Arab Emirates Human Vaccines Revenue (Million USD) and Growth Rate (2017-2025)
Figure Egypt Human Vaccines Revenue (Million USD) and Growth Rate (2017-2025)
Figure Nigeria Human Vaccines Revenue (Million USD) and Growth Rate (2017-2025)
Figure South Africa Human Vaccines Revenue (Million USD) and Growth Rate (2017-2025)
Figure Turkey Human Vaccines Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Middle East and Africa Human Vaccines Revenue (Million USD) and Growth Rate (2017-2025)
Table Global Human Vaccines Revenue and Revenue Share by Product Type (2017-2018)
Figure Global Measles-RubellaVaccine Revenue and Growth Rate (2017-2018)
Figure Global Dengue Vaccine Revenue and Growth Rate (2017-2018)
Figure Global TD Vaccine Revenue and Growth Rate (2017-2018)
Figure Global Chikungunya Vaccine Revenue and Growth Rate (2017-2018)
Figure Global Hepatitis A Vaccine Revenue and Growth Rate (2017-2018)
Figure Global Zika Vaccine Revenue and Growth Rate (2017-2018)
Figure Global Typhoid Conjugate Vaccine Revenue and Growth Rate (2017-2018)
Table Global Human Vaccines Revenue and Revenue Share by End User (2017-2018)
Figure Global Children Revenue and Growth Rate (2017-2018)
Figure Global Adults Revenue and Growth Rate (2017-2018)
Table Global Human Vaccines Revenue by Regions (2017-2018)
Figure North America Human Vaccines Growth Rate (2017-2018)
Figure North America Human Vaccines Revenue and Growth Rate (2017-2018)
Figure North America Human Vaccines by Countries (2017-2018)
Figure North America Human Vaccines Revenue (Million USD) by Countries (2017-2018)
Figure United States Human Vaccines Growth Rate (2017-2018)
Figure United States Human Vaccines Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Canada Human Vaccines Growth Rate (2017-2018)
Figure Canada Human Vaccines Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Mexico Human Vaccines Growth Rate (2017-2018)
Figure Mexico Human Vaccines Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Europe Human Vaccines Growth Rate (2017-2018)
Figure Europe Human Vaccines Revenue and Growth Rate (2017-2018)
Figure Europe Human Vaccines by Countries (2017-2018)
Figure Europe Human Vaccines Revenue (Million USD) by Countries (2017-2018)
Figure Germany Human Vaccines Growth Rate (2017-2018)
Figure Germany Human Vaccines Revenue (Millions USD) and Growth Rate (2017-2018)
Figure France Human Vaccines Growth Rate (2017-2018)
Figure France Human Vaccines Revenue (Millions USD) and Growth Rate (2017-2018)
Figure UK Human Vaccines Growth Rate (2017-2018)
Figure UK Human Vaccines Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Russia Human Vaccines Growth Rate (2017-2018)
Figure Russia Human Vaccines Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Italy Human Vaccines Growth Rate (2017-2018)
Figure Italy Human Vaccines Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Europe Human Vaccines Growth Rate (2017-2018)
Figure Rest of Europe Human Vaccines Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Asia-Pacific Human Vaccines Growth Rate (2017-2018)
Figure Asia-Pacific Human Vaccines Revenue and Growth Rate (2017-2018)
Figure Asia-Pacific Human Vaccines by Countries (2017-2018)
Figure Asia-Pacific Human Vaccines Revenue (Million USD) by Countries (2017-2018)
Figure China Human Vaccines Growth Rate (2017-2018)
Figure China Human Vaccines Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Japan Human Vaccines Growth Rate (2017-2018)
Figure Japan Human Vaccines Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Korea Human Vaccines Growth Rate (2017-2018)
Figure Korea Human Vaccines Revenue (Millions USD) and Growth Rate (2017-2018)
Figure India Human Vaccines Growth Rate (2017-2018)
Figure India Human Vaccines Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Southeast Asia Human Vaccines Growth Rate (2017-2018)
Figure Southeast Asia Human Vaccines Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Human Vaccines Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Human Vaccines Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South America Human Vaccines Growth Rate (2017-2018)
Figure South America Human Vaccines Revenue and Growth Rate (2017-2018)
Figure South America Human Vaccines by Countries (2017-2018)
Figure South America Human Vaccines Revenue (Million USD) by Countries (2017-2018)
Figure Brazil Human Vaccines Growth Rate (2017-2018)
Figure Brazil Human Vaccines Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Argentina Human Vaccines Growth Rate (2017-2018)
Figure Argentina Human Vaccines Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Columbia Human Vaccines Growth Rate (2017-2018)
Figure Columbia Human Vaccines Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of South America Human Vaccines Growth Rate (2017-2018)
Figure Rest of South America Human Vaccines Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Middle East and Africa Human Vaccines Growth Rate (2017-2018)
Figure Middle East and Africa Human Vaccines Revenue and Growth Rate (2017-2018)
Figure Middle East and Africa Human Vaccines by Countries (2017-2018)
Figure Middle East and Africa Human Vaccines Revenue (Million USD) by Countries (2017-2018)
Figure Saudi Arabia Human Vaccines Growth Rate (2017-2018)
Figure Saudi Arabia Human Vaccines Revenue (Millions USD) and Growth Rate (2017-2018)
Figure United Arab Emirates Human Vaccines Growth Rate (2017-2018)
Figure United Arab Emirates Human Vaccines Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Egypt Human Vaccines Growth Rate (2017-2018)
Figure Egypt Human Vaccines Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Nigeria Human Vaccines Growth Rate (2017-2018)
Figure Nigeria Human Vaccines Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South Africa Human Vaccines Growth Rate (2017-2018)
Figure South Africa Human Vaccines Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Turkey Human Vaccines Growth Rate (2017-2018)
Figure Turkey Human Vaccines Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Human Vaccines Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Human Vaccines Revenue (Millions USD) and Growth Rate (2017-2018)
Table Merck & Co., Inc. Human Vaccines Financial Overview (2017-2017)
Table AstraZeneca Human Vaccines Financial Overview (2017-2017)
Table Johnson & Johnson Human Vaccines Financial Overview (2017-2017)
Table GlaxoSmithKline plc Human Vaccines Financial Overview (2017-2017)
Table Sanofi Human Vaccines Financial Overview (2017-2017)
Table Pfizer, Inc. Human Vaccines Financial Overview (2017-2017)
Table Novartis AG Human Vaccines Financial Overview (2017-2017)
Table Bharat Biotech Human Vaccines Financial Overview (2017-2017)
Table Emergent BioSolutions, Inc. Human Vaccines Financial Overview (2017-2017)
Table CSL Limited Human Vaccines Financial Overview (2017-2017)
Table Bavarian Nordic Human Vaccines Financial Overview (2017-2017)
Table Shenzhen Kangtai Biological Products Co., Ltd. Human Vaccines Financial Overview (2017-2017)
Figure Global Human Vaccines Revenue (Millions USD) and Growth Rate (2018-2025)
Table Human Vaccines Market Forecast by Regions (2018-2025)
Figure North America Human Vaccines Market Forecast (2018-2025)
Figure United States Human Vaccines Market Forecast (2018-2025)
Figure Canada Human Vaccines Market Forecast (2018-2025)
Figure Mexico Human Vaccines Market Forecast (2018-2025)
Figure Europe Human Vaccines Market Forecast (2018-2025)
Figure Germany Human Vaccines Market Forecast (2018-2025)
Figure France Human Vaccines Market Forecast (2018-2025)
Figure UK Human Vaccines Market Forecast (2018-2025)
Figure Russia Human Vaccines Market Forecast (2018-2025)
Figure Italy Human Vaccines Market Forecast (2018-2025)
Figure Rest of Europe Human Vaccines Market Forecast (2018-2025)
Figure Asia-Pacific Human Vaccines Market Forecast (2018-2025)
Figure China Human Vaccines Market Forecast (2018-2025)
Figure Japan Human Vaccines Market Forecast (2018-2025)
Figure Korea Human Vaccines Market Forecast (2018-2025)
Figure India Human Vaccines Market Forecast (2018-2025)
Figure Southeast Asia Human Vaccines Market Forecast (2018-2025)
Figure Rest of Asia-Pacific Human Vaccines Market Forecast (2018-2025)
Figure South America Human Vaccines Market Forecast (2018-2025)
Figure Brazil Human Vaccines Market Forecast (2018-2025)
Figure Argentina Human Vaccines Market Forecast (2018-2025)
Figure Columbia Human Vaccines Market Forecast (2018-2025)
Figure Rest of South America Human Vaccines Market Forecast (2018-2025)
Figure Middle East and Africa Human Vaccines Market Forecast (2018-2025)
Figure Saudi Arabia Human Vaccines Market Forecast (2018-2025)
Figure United Arab Emirates Human Vaccines Market Forecast (2018-2025)
Figure Egypt Human Vaccines Market Forecast (2018-2025)
Figure Nigeria Human Vaccines Market Forecast (2018-2025)
Figure South Africa Human Vaccines Market Forecast (2018-2025)
Figure Turkey Human Vaccines Market Forecast (2018-2025)
Figure Rest of Middle East and Africa Human Vaccines Market Forecast (2018-2025)
Figure Global Human Vaccines Forecast by Product Type (2018-2025)
Figure Global Human Vaccines Market Share Forecast by Product Type (2018-2025)
Figure Global Human Vaccines Forecast by Product Type (2018-2025)
Figure Global Human Vaccines Forecast by End User (2018-2025)
Figure Global Human Vaccines Market Share Forecast by End User (2018-2025)
Figure Global Human Vaccines Forecast by End User (2018-2025)
Please Note: Data related to the Companies are subject to Availability.
Research Methodology
We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.
Data Mining
Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.
Data Collection Matrix
|
Data Collection Matrix |
Supply Side |
Demand Side |
|
Primary Data Sources |
|
|
|
Secondary Data Sources |
|
|
Market Modeling and Forecasting
We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.
- Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
- Number of patients for particular device or medical procedure and
- Repeated use of particular device depending on health and condition of patient
- Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.
We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.
Data Validation
We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.
Data Triangulation
Industry Analysis
|
Qualitative Data |
Quantitative Data (2017-2025) |
|
|